Jazz (JAZZ) Phase 3 Study of JZP-258 in Adult Narcolepsy Patients Shows Statistically Significant Differences in Primary Endpoint
Tweet Send to a Friend
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive top-line results from the global, double-blind, placebo-controlled, randomized-withdrawal, multicenter Phase 3 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
